Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Christopher R Moyes und 27 weiteren Autor:innen. Beteiligte Einrichtung: Kallyope, Inc., 430 East 29th Street, 10th Floor, New York, New York 10016, United States. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Metabolic Diseases, Phenylpropionates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Kallyope, Inc..
Abstract (Originalsprache)
Bariatric surgery provides long-term and robust weight loss in most patients. One leading hypothesis for this profound efficacy focuses on the increased activation of gut enteroendocrine cells (EECs), resulting in enhanced secretion of satiety hormones. We describe herein an approach using a combination of gut-targeted small molecules to stimulate intestinal nutrient receptors and mirror some of the hormone effects of bariatric surgery. In preclinical studies, administration of GPR40 agonist K-757 in combination with GPR119 agonist K-833 resulted in robust increases in the level of circulating hormones. In initial clinical studies, pharmacokinetics and pharmacodynamics for each molecule were characterized and largely recapitulated the effects of the individual compounds in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kallyope, Inc., 430 East 29th Street, 10th Floor, New York, New York 10016, United States.
ORCID-Profile: Monika J M Murphy, Michael R Luzung, Iyassu K Sebhat
Förderung
- Kallyope, Inc.
Zitieren
APA
Moyes, C. R., He, S., Mathieu, S., Lehman, S. L., Francisco, M. T., Vardy, E., Terracina, G., Galstian, A., Murphy, M. J. M., Poterewicz, G., Kosinski, D., Yang, X., Zheng, S., Chan, B., Consolati, M. J., Tschirret-Guth, R., Luzung, M. R., Saklatvala, R., Rak, G., …, & Sebhat, I. K. (2025). Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01030
Vancouver
Moyes CR, He S, Mathieu S, Lehman SL, Francisco MT, Vardy E, et al. Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01030
BibTeX
@article{Moyes2025,
author = {Moyes, Christopher R and He, Shuwen and Mathieu, Simon and Lehman, Sara L and Francisco, Macrina T and Vardy, Eyal and Terracina, Giuseppe and Galstian, Ani and Murphy, Monika J M and Poterewicz, Gregory and Kosinski, Danny and Yang, Xiaodong and Zheng, Shuqin and Chan, Bryan and Consolati, Matthew J and Tschirret-Guth, Richard and Luzung, Michael R and Saklatvala, Robert and Rak, Gregory and Barretto, Robert and Talaty, Jennifer and Vance, Annemarie and Zhang, Hong and Liu, Jiajun and Weber, Ann E and Lauring, Brett and Pinto, Shirly and Sebhat, Iyassu K},
title = {Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01030}
}
EUVIMED